Literature DB >> 16216152

Expanding treatment of tobacco dependence.

Debra S Harris1, Robert M Anthenelli.   

Abstract

Nicotine dependence is the leading preventable cause of adult morbidity and mortality in the world. New research on the treatment of this disorder ranges from studies evaluating access to treatment to studies elucidating the molecular mechanisms of nicotine addiction. As our understanding of the neurobiology of tobacco addiction grows, the number of potential therapeutic targets by which we can intervene in this pernicious disorder also increases. This paper presents an overview of recent research trends in the treatment of tobacco dependence. We review several novel mechanisms of action that may serve as therapeutic targets for the pharmacologic treatment of tobacco dependence, including drugs that affect monamine oxidase, selective nicotinic receptors, glutamate and gamma-aminobutyric acid receptors, and the endocannabinoid system. For each of these therapeutic targets, we discuss medications in development that affect these pathophysiologic mechanisms.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16216152     DOI: 10.1007/s11920-005-0034-3

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  59 in total

1.  Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs.

Authors:  F E Pontieri; G Tanda; F Orzi; G Di Chiara
Journal:  Nature       Date:  1996-07-18       Impact factor: 49.962

2.  Absorption and presystemic metabolism of selegiline hydrochloride at different regions in the gastrointestinal tract in healthy males.

Authors:  J S Barrett; P Szego; S Rohatagi; R J Morales; K E De Witt; G Rajewski; J Ireland
Journal:  Pharm Res       Date:  1996-10       Impact factor: 4.200

Review 3.  Cellular mechanisms of nicotine addiction.

Authors:  J A Dani; M De Biasi
Journal:  Pharmacol Biochem Behav       Date:  2001-12       Impact factor: 3.533

4.  Low monoamine oxidase B in peripheral organs in smokers.

Authors:  Joanna S Fowler; Jean Logan; Gene-Jack Wang; Nora D Volkow; Frank Telang; Wei Zhu; Dinko Franceschi; Naomi Pappas; Richard Ferrieri; Colleen Shea; Victor Garza; Youwen Xu; David Schlyer; S John Gatley; Yu-Shin Ding; David Alexoff; Donald Warner; Noelwah Netusil; Pauline Carter; Millard Jayne; Payton King; Paul Vaska
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-12       Impact factor: 11.205

5.  A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation.

Authors:  R Biberman; R Neumann; I Katzir; Y Gerber
Journal:  Addiction       Date:  2003-10       Impact factor: 6.526

6.  Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716).

Authors:  Caroline Cohen; Ghislaine Perrault; Guy Griebel; Philippe Soubrié
Journal:  Neuropsychopharmacology       Date:  2005-01       Impact factor: 7.853

7.  The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis.

Authors:  Daniela Cota; Giovanni Marsicano; Matthias Tschöp; Yvonne Grübler; Cornelia Flachskamm; Mirjam Schubert; Dorothee Auer; Alexander Yassouridis; Christa Thöne-Reineke; Sylvia Ortmann; Federica Tomassoni; Cristina Cervino; Enzo Nisoli; Astrid C E Linthorst; Renato Pasquali; Beat Lutz; Günter K Stalla; Uberto Pagotto
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

8.  A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation.

Authors:  Tony P George; Jennifer C Vessicchio; Angelo Termine; Peter I Jatlow; Thomas R Kosten; Stephanie S O'Malley
Journal:  Biol Psychiatry       Date:  2003-01-15       Impact factor: 13.382

9.  Psychopharmacological interactions between nicotine and ethanol.

Authors:  Jed E Rose; Lisa H Brauer; Frederique M Behm; Matthew Cramblett; Kevin Calkins; Dawn Lawhon
Journal:  Nicotine Tob Res       Date:  2004-02       Impact factor: 4.244

Review 10.  Clonidine for smoking cessation.

Authors:  S G Gourlay; L F Stead; N L Benowitz
Journal:  Cochrane Database Syst Rev       Date:  2004
View more
  3 in total

1.  Functional Upregulation of α4* Nicotinic Acetylcholine Receptors in VTA GABAergic Neurons Increases Sensitivity to Nicotine Reward.

Authors:  Jennifer Ngolab; Liwang Liu; Rubing Zhao-Shea; Guangping Gao; Paul D Gardner; Andrew R Tapper
Journal:  J Neurosci       Date:  2015-06-03       Impact factor: 6.167

2.  Smoking cessation: an economic analysis and review of varenicline.

Authors:  Michele A Faulkner
Journal:  Clinicoecon Outcomes Res       Date:  2009-06-24

3.  Increased CRF signalling in a ventral tegmental area-interpeduncular nucleus-medial habenula circuit induces anxiety during nicotine withdrawal.

Authors:  Rubing Zhao-Shea; Steven R DeGroot; Liwang Liu; Markus Vallaster; Xueyan Pang; Qin Su; Guangping Gao; Oliver J Rando; Gilles E Martin; Olivier George; Paul D Gardner; Andrew R Tapper
Journal:  Nat Commun       Date:  2015-04-21       Impact factor: 14.919

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.